ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > waiting

<< Previous

Bullboard Posts

Next >>

Comment by DavidKingCanadaon Mar 21, 2022 2:52pm

113 Views

Post# 34532175

RE:waiting

M101 PMN is a sham.

Do you actually think a small unknown Canadian Pharma Company will come up with the most valuable Medicine in Human History while all the other Pharma Companies worth BILLIONS will sit back and watch their Stock tumble?

PMN is nothing more than a Pump and Dump scheme.

All the long term holders know that but are too deeply invested that they keep Pumping.

M101 I do respect you for keeping it real!

<< Previous

Bullboard Posts

Next >>

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload